Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BA 1504/7-2)
Bundesministerium für Bildung und Forschung (01EE1404A)
Technische Universität Dresden
Received: 28 September 2020
Accepted: 6 May 2021
First Online: 2 July 2021
: Data were collected as part of the routine process. In case, additional data were acquired within a study protocol this was approved by the Ethics Committee of the Medical Faculty of the Technische Universität Dresden (EK 60022010 and EK290082014) and subjects consented after comprehensive information. This analysis was carried out in accordance to the APA ethical standards (American Psychiatric Association 2003) and the Declaration of Helsinki (World Medical Association CitationRef removed).
: Not applicable.
: AP has received speakers honoraria and travel support from Janssen and Lundbeck. KL has been an advisor to and received speakers honoraria and travel support from Janssen, Lundbeck, Otsuka and Recordati. She received grant support from Janssen and Otsuka. JM, AY has received speakers honoraria and travel support from Janssen and Lundbeck, Sunovion, COMPASS and Livanova. CC has been a consultant and/or advisor to or have received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. AB, SP, MB state to have no conflict of interest.